The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 09, 2023

Filed:

Jul. 27, 2017
Applicant:

Obi Pharma, Inc., Taipei, TW;

Inventors:

Cheng-Der Tony Yu, San Diego, CA (US);

Peiwen Yu, San Diego, CA (US);

Kuo-Pao Lai, Taipei, TW;

Wei-Han Lee, Taipei, TW;

I-Ju Chen, Taipei, TW;

Shu-Yi Lin, Taipei, TW;

Yih-Huang Hsieh, Taipei, TW;

Assignee:

OBI PHARMA, INC., Taipei, TW;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/00118 (2018.08); A61K 39/001173 (2018.08); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/627 (2013.01); A61K 2039/64 (2013.01);
Abstract

The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.


Find Patent Forward Citations

Loading…